Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shanghai Institute of Materia Medica Successfully Develops China’s First Quinolone Drug

This article was originally published in PharmAsia News

Executive Summary

Shanghai Institute of Materia Medica has successfully developed China's first quinolone drug - antofloxacin hydrochloride - with intellectual property rights. This represents an achievement under the country's new drug innovation and production program (PharmAsia News, May 11, 2009). With a decade's research and three phases of clinical trials, the drug has gained China's rare Class-I new drug certification and is ready to market. Compared to recent fourth-generation generic quinolone drugs such as prulifloxacin, gemifloxacin and moxifloxacin, the new drug demonstrates advantages in its metabolic characteristics and production costs. It offers long-acting effectiveness of up to 95 percent with the lowest oral dosage for respiratory, urinary and skin infections, making it affordable to the general public. Moreover, its phototoxicity is markedly lower than current similar products including lomefloxacin, sparfloxacin, fleroxacin and ciprofloxacin. (Click here for more - Chinese Language)

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts